GUIDOBONI, Massimo
 Distribuzione geografica
Continente #
AS - Asia 2.333
NA - Nord America 2.217
EU - Europa 771
SA - Sud America 362
AF - Africa 65
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.752
Nazione #
US - Stati Uniti d'America 2.112
SG - Singapore 945
CN - Cina 409
IT - Italia 292
BR - Brasile 266
BD - Bangladesh 264
VN - Vietnam 236
HK - Hong Kong 206
FI - Finlandia 96
DE - Germania 87
IN - India 62
FR - Francia 51
GB - Regno Unito 48
ID - Indonesia 48
UA - Ucraina 48
CA - Canada 46
MX - Messico 42
RU - Federazione Russa 42
AR - Argentina 39
JP - Giappone 38
ZA - Sudafrica 28
IQ - Iraq 19
NL - Olanda 19
AT - Austria 17
TR - Turchia 17
EC - Ecuador 16
PH - Filippine 16
PL - Polonia 16
ES - Italia 12
CO - Colombia 11
SE - Svezia 10
MA - Marocco 9
KE - Kenya 8
LT - Lituania 8
PK - Pakistan 8
UZ - Uzbekistan 8
VE - Venezuela 8
PY - Paraguay 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
JO - Giordania 6
MY - Malesia 6
EG - Egitto 5
NP - Nepal 5
BA - Bosnia-Erzegovina 4
CH - Svizzera 4
CR - Costa Rica 4
HN - Honduras 4
UY - Uruguay 4
GR - Grecia 3
IL - Israele 3
KG - Kirghizistan 3
PE - Perù 3
PS - Palestinian Territory 3
TN - Tunisia 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
IE - Irlanda 2
KH - Cambogia 2
MN - Mongolia 2
PA - Panama 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AZ - Azerbaigian 1
BE - Belgio 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GN - Guinea 1
GP - Guadalupe 1
KI - Kiribati 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MV - Maldive 1
NG - Nigeria 1
NI - Nicaragua 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
Totale 5.750
Città #
Singapore 566
San Jose 402
Ashburn 317
Santa Clara 285
Hong Kong 202
Beijing 113
Ho Chi Minh City 86
Helsinki 85
Los Angeles 78
New York 75
Hanoi 52
Council Bluffs 46
Houston 43
Dallas 41
Jakarta 38
Tokyo 38
Woodbridge 37
Fairfield 36
Chicago 35
Jacksonville 30
Lauterbourg 28
São Paulo 28
Mexico City 27
Milan 25
Bologna 24
Buffalo 23
Ferrara 23
Nuremberg 22
Hefei 21
Orem 20
Shanghai 20
Dearborn 16
Rome 16
Seattle 16
Toronto 16
Atlanta 14
Warsaw 14
Brooklyn 13
Frankfurt am Main 12
San Francisco 12
Baghdad 11
Chennai 11
Da Nang 11
Johannesburg 11
London 11
Montreal 11
Portland 11
Cambridge 10
Chandler 10
Falkenstein 10
Naples 10
Wilmington 10
Haiphong 9
Curitiba 8
Phoenix 8
Rio de Janeiro 8
Boardman 7
Manchester 7
Tashkent 7
Vienna 7
Boston 6
Denver 6
Guangzhou 6
Hải Dương 6
Izmir 6
Mumbai 6
Nanjing 6
Salt Lake City 6
San Diego 6
Stockholm 6
Amman 5
Amsterdam 5
Biên Hòa 5
Guarulhos 5
Guayaquil 5
Lappeenranta 5
Manila 5
Nairobi 5
Nanchang 5
New Delhi 5
Parma 5
Poplar 5
Princeton 5
Quito 5
Ann Arbor 4
Assago 4
Asunción 4
Belo Horizonte 4
Brescia 4
Charlotte 4
Forlì 4
Montevideo 4
Monza 4
Moscow 4
Munich 4
Newark 4
Ottawa 4
Pasadena 4
San José 4
The Dalles 4
Totale 3.377
Nome #
The long-term prognostic impact of sentinel lymph node biopsy in patients with primary cutaneous melanoma: a prospective study with 10-year follow-up 190
ML Models Built Using Clinical Parameters and Radiomic Features Extracted from 18F-Choline PET/CT for the Prediction of Biochemical Recurrence after Metastasis-Directed Therapy in Patients with Oligometastatic Prostate Cancer 170
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis 170
Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients 155
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 140
Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma 134
Nectin-4-Targeting Radiotracers: Novel Theranostic Agents for Precision Oncology in Cancer 131
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis 129
Prognostic value of microsatellite instability and intratumor activated cytotoxic lymphocytes in colon cancer 128
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial 127
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study 119
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma 118
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 107
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 101
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 98
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 96
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 94
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). 92
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy) 89
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 88
Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications 87
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 86
Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions 85
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial 84
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 84
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 82
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience 78
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: A multicenter prospective trial 77
Chlamydia infection and lymphomas: Association beyond ocular adnexal lymphomas highlighted by multiple detection methods 77
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 76
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile 76
Circulating memory B-cell receptor repertoire analysis identifies novel candidate antibodies against metastatic melanoma in immunotherapy-responsive patients 76
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 76
First-line, Fixed-Duration Nivolumab plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401 75
Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas - Differences between high-grade and low-grade cases 75
Dabrafenib-trametinib combination in 'field-practice': an Italian experience 74
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 74
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study 73
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 72
First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted Therapy study) 70
Outcomes in patients with BRAFV600–mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib 69
Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome 69
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 68
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 67
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma 66
ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy 65
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data 64
Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis 64
Correspondence re: Samowitz et al., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev., 10 : 917-923, 2001 64
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability 57
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 55
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4(+)CD25(++)Foxp3(+) regulatory T-cells in advanced melanoma patients 54
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 52
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response 46
IGKV3 Proteins as Candidate "Off-the-Shelf" Vaccines for Kappa-Light Chain-Restricted B-Cell Non-Hodgkin Lymphomas 46
Melanoma vaccines in development 45
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy 44
Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type 41
Retinoic acid inhibits IL-6-dependent but not constitutive STAT3 activation in Epstein-Barr virus-immortalized B lymphocytes 40
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) 39
Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial 38
High serum levels of soluble CD40-L in patients with undifferentiated nasopharyngeal carcinoma: pathogenic and clinical relevance 38
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 38
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas 38
Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma 36
Retinoic acid stabilizes p27(Kip1) in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45(Skp2) and Cks1 proteins 35
Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study 35
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 34
IDIOTYPIC VACCIN 34
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma 33
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study 33
Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes 33
Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis 30
Ipilimumab in advanced melanoma: reports of long-lasting responses 29
Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies. 29
Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: Pathogenic role and therapeutic perspectives 28
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study 27
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma 26
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax) 24
Epigenetic remodelling of DNA in cancer 24
Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study 23
IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia 23
MicroRNAs and dendritic cell-based vaccination in melanoma patients 21
Latent membrane protein 1 deletion mutants accumulate in Reed-Sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma 20
Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone 19
Totale 5.896
Categoria #
all - tutte 30.979
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 259
Totale 31.238


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/202257 4 4 1 2 1 2 1 9 3 4 3 23
2022/202344 6 4 1 4 6 4 1 3 6 0 8 1
2023/2024192 2 6 3 1 0 50 0 51 0 3 19 57
2024/20251.264 37 103 67 7 186 164 31 41 190 206 132 100
2025/20264.080 266 108 267 410 522 208 442 215 406 502 406 328
Totale 5.896